GlassScriptPhysician profile
David J Hobbs
NPI 1639158702
$4,868.65
in general payments reported to CMS, 2019-2025
15 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $668 · 2021: $684 · 2022: $567 · 2023: $784 · 2024: $1,188 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,363.86 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $477.53 | 2022-2024 | Arexvy |
| Amarin Pharma, INC. | $222.68 | 2019-2021 | |
| Novo Nordisk INC | $162.96 | 2022 | |
| Amgen INC. | $152.20 | 2025 | Evenity |
| Biohaven Pharmaceuticals, INC. | $124.37 | 2021 | |
| Arbor Pharmaceuticals, INC. | $102.31 | 2019-2021 | |
| Ge Healthcare | $79.46 | 2022-2023 | |
| Astellas Pharma US INC | $75.01 | 2019-2021 | |
| Exact Sciences Corporation | $26.69 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $19.00 | 2025 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $17.09 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.67 | 2020 | |
| Azurity Pharmaceuticals, INC. | $15.85 | 2023 | Edarbi |
| Covidien LP | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hobbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.